Notably, reduction in tumor size (21.4%) was seen in one CPI-naïve patient (KRAS G12D mutation positive, PD-L1 CPS ≥ 1) treated at 6 mg QW with disease control lasting 59.4 weeks before progression. The gene discussed is KRAS; the disease is neoplasm.